nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—AURKA—peripheral nervous system neoplasm	0.14	0.267	CbGaD
Crizotinib—MET—peripheral nervous system neoplasm	0.137	0.261	CbGaD
Crizotinib—ALK—peripheral nervous system neoplasm	0.117	0.224	CbGaD
Crizotinib—AURKA—Epirubicin—peripheral nervous system neoplasm	0.116	0.5	CbGbCtD
Crizotinib—NTRK1—peripheral nervous system neoplasm	0.114	0.218	CbGaD
Crizotinib—AURKA—Doxorubicin—peripheral nervous system neoplasm	0.0616	0.266	CbGbCtD
Crizotinib—ABCB1—peripheral nervous system neoplasm	0.016	0.0305	CbGaD
Crizotinib—CYP3A5—Tretinoin—peripheral nervous system neoplasm	0.00896	0.0386	CbGbCtD
Crizotinib—ABCB1—Topotecan—peripheral nervous system neoplasm	0.00628	0.0271	CbGbCtD
Crizotinib—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.00628	0.0271	CbGbCtD
Crizotinib—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.00435	0.0188	CbGbCtD
Crizotinib—CYP3A5—Vincristine—peripheral nervous system neoplasm	0.00412	0.0177	CbGbCtD
Crizotinib—CYP3A5—Etoposide—peripheral nervous system neoplasm	0.00377	0.0163	CbGbCtD
Crizotinib—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.00376	0.0162	CbGbCtD
Crizotinib—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.0035	0.0151	CbGbCtD
Crizotinib—ACVR1—pes—peripheral nervous system neoplasm	0.0033	0.0767	CbGeAlD
Crizotinib—ABCB1—Vincristine—peripheral nervous system neoplasm	0.00268	0.0115	CbGbCtD
Crizotinib—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.0025	0.0108	CbGbCtD
Crizotinib—ABCB1—Etoposide—peripheral nervous system neoplasm	0.00245	0.0106	CbGbCtD
Crizotinib—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.00167	0.00722	CbGbCtD
Crizotinib—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.0016	0.00692	CbGbCtD
Crizotinib—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.00147	0.00634	CbGbCtD
Crizotinib—LTK—tongue—peripheral nervous system neoplasm	0.00141	0.0329	CbGeAlD
Crizotinib—RPS6KB1—forelimb—peripheral nervous system neoplasm	0.00135	0.0313	CbGeAlD
Crizotinib—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.001	0.00432	CbGbCtD
Crizotinib—MERTK—ganglion—peripheral nervous system neoplasm	0.000931	0.0217	CbGeAlD
Crizotinib—NTRK1—trigeminal ganglion—peripheral nervous system neoplasm	0.000888	0.0207	CbGeAlD
Crizotinib—EPHA4—nerve—peripheral nervous system neoplasm	0.000797	0.0185	CbGeAlD
Crizotinib—EPHA4—ganglion—peripheral nervous system neoplasm	0.000787	0.0183	CbGeAlD
Crizotinib—EPHA4—tongue—peripheral nervous system neoplasm	0.000778	0.0181	CbGeAlD
Crizotinib—EPHA7—cerebellum—peripheral nervous system neoplasm	0.000674	0.0157	CbGeAlD
Crizotinib—FES—parotid gland—peripheral nervous system neoplasm	0.000635	0.0148	CbGeAlD
Crizotinib—MET—brainstem—peripheral nervous system neoplasm	0.000563	0.0131	CbGeAlD
Crizotinib—DCLK1—trigeminal ganglion—peripheral nervous system neoplasm	0.000557	0.013	CbGeAlD
Crizotinib—FER—trigeminal ganglion—peripheral nervous system neoplasm	0.00052	0.0121	CbGeAlD
Crizotinib—EPHA5—trigeminal ganglion—peripheral nervous system neoplasm	0.00052	0.0121	CbGeAlD
Crizotinib—TNK1—trigeminal ganglion—peripheral nervous system neoplasm	0.000515	0.012	CbGeAlD
Crizotinib—IKBKE—cerebellum—peripheral nervous system neoplasm	0.000511	0.0119	CbGeAlD
Crizotinib—MAP4K2—trigeminal ganglion—peripheral nervous system neoplasm	0.000493	0.0115	CbGeAlD
Crizotinib—TESK1—trigeminal ganglion—peripheral nervous system neoplasm	0.00047	0.0109	CbGeAlD
Crizotinib—TYRO3—brainstem—peripheral nervous system neoplasm	0.000461	0.0107	CbGeAlD
Crizotinib—NUAK2—trigeminal ganglion—peripheral nervous system neoplasm	0.000446	0.0104	CbGeAlD
Crizotinib—CASK—Irinotecan—Topotecan—peripheral nervous system neoplasm	0.000445	0.146	CbGdCrCtD
Crizotinib—TESK1—parotid gland—peripheral nervous system neoplasm	0.000443	0.0103	CbGeAlD
Crizotinib—ACVR1—trigeminal ganglion—peripheral nervous system neoplasm	0.000443	0.0103	CbGeAlD
Crizotinib—MAP3K12—trigeminal ganglion—peripheral nervous system neoplasm	0.000443	0.0103	CbGeAlD
Crizotinib—IGF1R—brainstem—peripheral nervous system neoplasm	0.000442	0.0103	CbGeAlD
Crizotinib—NUAK2—parotid gland—peripheral nervous system neoplasm	0.00042	0.00979	CbGeAlD
Crizotinib—IGF1R—Irinotecan—Topotecan—peripheral nervous system neoplasm	0.000419	0.137	CbGdCrCtD
Crizotinib—ACVR1—parotid gland—peripheral nervous system neoplasm	0.000417	0.00972	CbGeAlD
Crizotinib—BMP2K—trigeminal ganglion—peripheral nervous system neoplasm	0.000417	0.00972	CbGeAlD
Crizotinib—RIPK2—trigeminal ganglion—peripheral nervous system neoplasm	0.0004	0.00931	CbGeAlD
Crizotinib—MAP3K12—brainstem—peripheral nervous system neoplasm	0.000392	0.00912	CbGeAlD
Crizotinib—STK35—brainstem—peripheral nervous system neoplasm	0.000384	0.00893	CbGeAlD
Crizotinib—RIPK2—parotid gland—peripheral nervous system neoplasm	0.000377	0.00878	CbGeAlD
Crizotinib—TBK1—trigeminal ganglion—peripheral nervous system neoplasm	0.000371	0.00864	CbGeAlD
Crizotinib—TYK2—trigeminal ganglion—peripheral nervous system neoplasm	0.000369	0.00858	CbGeAlD
Crizotinib—RPS6KB1—trigeminal ganglion—peripheral nervous system neoplasm	0.000357	0.00831	CbGeAlD
Crizotinib—PTK2—Irinotecan—Topotecan—peripheral nervous system neoplasm	0.000356	0.116	CbGdCrCtD
Crizotinib—LCK—trigeminal ganglion—peripheral nervous system neoplasm	0.000355	0.00826	CbGeAlD
Crizotinib—AXL—trigeminal ganglion—peripheral nervous system neoplasm	0.000353	0.00823	CbGeAlD
Crizotinib—TBK1—parotid gland—peripheral nervous system neoplasm	0.00035	0.00815	CbGeAlD
Crizotinib—TYK2—parotid gland—peripheral nervous system neoplasm	0.000348	0.00809	CbGeAlD
Crizotinib—EPHA4—brainstem—peripheral nervous system neoplasm	0.000342	0.00796	CbGeAlD
Crizotinib—SLK—trigeminal ganglion—peripheral nervous system neoplasm	0.00034	0.00792	CbGeAlD
Crizotinib—EPHB4—trigeminal ganglion—peripheral nervous system neoplasm	0.000338	0.00786	CbGeAlD
Crizotinib—RPS6KB1—parotid gland—peripheral nervous system neoplasm	0.000337	0.00784	CbGeAlD
Crizotinib—JAK2—trigeminal ganglion—peripheral nervous system neoplasm	0.000335	0.00781	CbGeAlD
Crizotinib—PRKD1—cerebellum—peripheral nervous system neoplasm	0.000334	0.00777	CbGeAlD
Crizotinib—EPHA2—trigeminal ganglion—peripheral nervous system neoplasm	0.000331	0.00771	CbGeAlD
Crizotinib—LIMK1—cerebellum—peripheral nervous system neoplasm	0.000329	0.00767	CbGeAlD
Crizotinib—MAP4K5—trigeminal ganglion—peripheral nervous system neoplasm	0.000323	0.00753	CbGeAlD
Crizotinib—TEK—trigeminal ganglion—peripheral nervous system neoplasm	0.000323	0.00753	CbGeAlD
Crizotinib—MAP3K3—trigeminal ganglion—peripheral nervous system neoplasm	0.000323	0.00753	CbGeAlD
Crizotinib—PRKD3—cerebellum—peripheral nervous system neoplasm	0.000321	0.00747	CbGeAlD
Crizotinib—SLK—parotid gland—peripheral nervous system neoplasm	0.000321	0.00747	CbGeAlD
Crizotinib—EPHB4—parotid gland—peripheral nervous system neoplasm	0.000319	0.00742	CbGeAlD
Crizotinib—DSTYK—cerebellum—peripheral nervous system neoplasm	0.000313	0.00729	CbGeAlD
Crizotinib—EPHA2—parotid gland—peripheral nervous system neoplasm	0.000312	0.00728	CbGeAlD
Crizotinib—EPHB6—trigeminal ganglion—peripheral nervous system neoplasm	0.000309	0.00719	CbGeAlD
Crizotinib—CASK—cerebellum—peripheral nervous system neoplasm	0.000306	0.00713	CbGeAlD
Crizotinib—MAP4K5—parotid gland—peripheral nervous system neoplasm	0.000305	0.0071	CbGeAlD
Crizotinib—MAP3K3—parotid gland—peripheral nervous system neoplasm	0.000305	0.0071	CbGeAlD
Crizotinib—YES1—trigeminal ganglion—peripheral nervous system neoplasm	0.000299	0.00695	CbGeAlD
Crizotinib—MAPK7—cerebellum—peripheral nervous system neoplasm	0.000297	0.0069	CbGeAlD
Crizotinib—STK10—trigeminal ganglion—peripheral nervous system neoplasm	0.000296	0.00689	CbGeAlD
Crizotinib—TAOK3—trigeminal ganglion—peripheral nervous system neoplasm	0.000295	0.00686	CbGeAlD
Crizotinib—EPHA8—cerebellum—peripheral nervous system neoplasm	0.000294	0.00683	CbGeAlD
Crizotinib—EPHB6—parotid gland—peripheral nervous system neoplasm	0.000291	0.00678	CbGeAlD
Crizotinib—YES1—parotid gland—peripheral nervous system neoplasm	0.000282	0.00656	CbGeAlD
Crizotinib—TAOK3—parotid gland—peripheral nervous system neoplasm	0.000278	0.00647	CbGeAlD
Crizotinib—MET—cerebellum—peripheral nervous system neoplasm	0.000278	0.00646	CbGeAlD
Crizotinib—CDK7—cerebellum—peripheral nervous system neoplasm	0.000268	0.00625	CbGeAlD
Crizotinib—TAOK2—cerebellum—peripheral nervous system neoplasm	0.000266	0.0062	CbGeAlD
Crizotinib—TAOK3—brainstem—peripheral nervous system neoplasm	0.000261	0.00607	CbGeAlD
Crizotinib—CSF1R—trigeminal ganglion—peripheral nervous system neoplasm	0.000258	0.006	CbGeAlD
Crizotinib—ACVR1B—cerebellum—peripheral nervous system neoplasm	0.000257	0.00597	CbGeAlD
Crizotinib—AURKA—Chlorambucil—Melphalan—peripheral nervous system neoplasm	0.000248	0.081	CbGdCrCtD
Crizotinib—JAK3—cerebellum—peripheral nervous system neoplasm	0.000245	0.0057	CbGeAlD
Crizotinib—DCLK1—cerebellum—peripheral nervous system neoplasm	0.000243	0.00566	CbGeAlD
Crizotinib—STK4—cerebellum—peripheral nervous system neoplasm	0.00024	0.00559	CbGeAlD
Crizotinib—FER—cerebellum—peripheral nervous system neoplasm	0.000227	0.00529	CbGeAlD
Crizotinib—TYRO3—cerebellum—peripheral nervous system neoplasm	0.000227	0.00529	CbGeAlD
Crizotinib—EPHA5—cerebellum—peripheral nervous system neoplasm	0.000227	0.00529	CbGeAlD
Crizotinib—TNK1—cerebellum—peripheral nervous system neoplasm	0.000225	0.00523	CbGeAlD
Crizotinib—BMPR1B—cerebellum—peripheral nervous system neoplasm	0.000222	0.00518	CbGeAlD
Crizotinib—TNK2—cerebellum—peripheral nervous system neoplasm	0.000218	0.00508	CbGeAlD
Crizotinib—IGF1R—cerebellum—peripheral nervous system neoplasm	0.000218	0.00508	CbGeAlD
Crizotinib—MAP4K2—cerebellum—peripheral nervous system neoplasm	0.000215	0.00501	CbGeAlD
Crizotinib—STK3—cerebellum—peripheral nervous system neoplasm	0.000212	0.00494	CbGeAlD
Crizotinib—TIE1—cerebellum—peripheral nervous system neoplasm	0.000212	0.00494	CbGeAlD
Crizotinib—TESK1—cerebellum—peripheral nervous system neoplasm	0.000205	0.00478	CbGeAlD
Crizotinib—ABL1—trigeminal ganglion—peripheral nervous system neoplasm	0.000204	0.00475	CbGeAlD
Crizotinib—MERTK—cerebellum—peripheral nervous system neoplasm	0.0002	0.00465	CbGeAlD
Crizotinib—LIMK2—cerebellum—peripheral nervous system neoplasm	0.000195	0.00454	CbGeAlD
Crizotinib—NUAK2—cerebellum—peripheral nervous system neoplasm	0.000194	0.00453	CbGeAlD
Crizotinib—ACVR1—cerebellum—peripheral nervous system neoplasm	0.000193	0.0045	CbGeAlD
Crizotinib—MAP3K12—cerebellum—peripheral nervous system neoplasm	0.000193	0.0045	CbGeAlD
Crizotinib—FLT3—cerebellum—peripheral nervous system neoplasm	0.000193	0.0045	CbGeAlD
Crizotinib—ABL1—parotid gland—peripheral nervous system neoplasm	0.000192	0.00448	CbGeAlD
Crizotinib—STK35—cerebellum—peripheral nervous system neoplasm	0.000189	0.0044	CbGeAlD
Crizotinib—ABL2—cerebellum—peripheral nervous system neoplasm	0.000184	0.00429	CbGeAlD
Crizotinib—BMP2K—cerebellum—peripheral nervous system neoplasm	0.000182	0.00424	CbGeAlD
Crizotinib—ABL1—brainstem—peripheral nervous system neoplasm	0.00018	0.0042	CbGeAlD
Crizotinib—PTK2B—cerebellum—peripheral nervous system neoplasm	0.000176	0.00409	CbGeAlD
Crizotinib—RIPK2—cerebellum—peripheral nervous system neoplasm	0.000174	0.00406	CbGeAlD
Crizotinib—AURKA—Irinotecan—Topotecan—peripheral nervous system neoplasm	0.000172	0.0563	CbGdCrCtD
Crizotinib—EPHA4—cerebellum—peripheral nervous system neoplasm	0.000169	0.00393	CbGeAlD
Crizotinib—CASK—Teniposide—Etoposide—peripheral nervous system neoplasm	0.000167	0.0545	CbGdCrCtD
Crizotinib—MAP3K2—cerebellum—peripheral nervous system neoplasm	0.000165	0.00385	CbGeAlD
Crizotinib—PTK2—cerebellum—peripheral nervous system neoplasm	0.000162	0.00377	CbGeAlD
Crizotinib—TBK1—cerebellum—peripheral nervous system neoplasm	0.000162	0.00377	CbGeAlD
Crizotinib—TYK2—cerebellum—peripheral nervous system neoplasm	0.000161	0.00374	CbGeAlD
Crizotinib—IRAK1—cerebellum—peripheral nervous system neoplasm	0.000159	0.0037	CbGeAlD
Crizotinib—RPS6KB1—cerebellum—peripheral nervous system neoplasm	0.000156	0.00363	CbGeAlD
Crizotinib—AXL—cerebellum—peripheral nervous system neoplasm	0.000154	0.00359	CbGeAlD
Crizotinib—SLK—cerebellum—peripheral nervous system neoplasm	0.000148	0.00346	CbGeAlD
Crizotinib—EPHB4—cerebellum—peripheral nervous system neoplasm	0.000147	0.00343	CbGeAlD
Crizotinib—JAK2—cerebellum—peripheral nervous system neoplasm	0.000146	0.00341	CbGeAlD
Crizotinib—TEK—cerebellum—peripheral nervous system neoplasm	0.000141	0.00328	CbGeAlD
Crizotinib—MAP4K5—cerebellum—peripheral nervous system neoplasm	0.000141	0.00328	CbGeAlD
Crizotinib—MAP3K3—cerebellum—peripheral nervous system neoplasm	0.000141	0.00328	CbGeAlD
Crizotinib—EPHB6—cerebellum—peripheral nervous system neoplasm	0.000135	0.00314	CbGeAlD
Crizotinib—YES1—cerebellum—peripheral nervous system neoplasm	0.00013	0.00303	CbGeAlD
Crizotinib—STK10—cerebellum—peripheral nervous system neoplasm	0.000129	0.00301	CbGeAlD
Crizotinib—TAOK3—cerebellum—peripheral nervous system neoplasm	0.000129	0.00299	CbGeAlD
Crizotinib—SRC—cerebellum—peripheral nervous system neoplasm	0.000125	0.00292	CbGeAlD
Crizotinib—Constipation—Tretinoin—peripheral nervous system neoplasm	0.000124	0.00143	CcSEcCtD
Crizotinib—Constipation—Isotretinoin—peripheral nervous system neoplasm	0.000124	0.00143	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Melphalan—peripheral nervous system neoplasm	0.000124	0.00143	CcSEcCtD
Crizotinib—Fatigue—Melphalan—peripheral nervous system neoplasm	0.000124	0.00143	CcSEcCtD
Crizotinib—Eye disorder—Cisplatin—peripheral nervous system neoplasm	0.000124	0.00142	CcSEcCtD
Crizotinib—Cardiac disorder—Cisplatin—peripheral nervous system neoplasm	0.000123	0.00141	CcSEcCtD
Crizotinib—Syncope—Alitretinoin—peripheral nervous system neoplasm	0.000121	0.0014	CcSEcCtD
Crizotinib—Hypoaesthesia—Etoposide—peripheral nervous system neoplasm	0.00012	0.00139	CcSEcCtD
Crizotinib—Anaemia—Vincristine—peripheral nervous system neoplasm	0.00012	0.00139	CcSEcCtD
Crizotinib—Urinary tract disorder—Etoposide—peripheral nervous system neoplasm	0.00012	0.00138	CcSEcCtD
Crizotinib—Mediastinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000119	0.00137	CcSEcCtD
Crizotinib—Oedema—Dactinomycin—peripheral nervous system neoplasm	0.000119	0.00137	CcSEcCtD
Crizotinib—Fluid retention—Doxorubicin—peripheral nervous system neoplasm	0.000119	0.00137	CcSEcCtD
Crizotinib—Urethral disorder—Etoposide—peripheral nervous system neoplasm	0.000119	0.00137	CcSEcCtD
Crizotinib—Loss of consciousness—Alitretinoin—peripheral nervous system neoplasm	0.000119	0.00137	CcSEcCtD
Crizotinib—Infection—Dactinomycin—peripheral nervous system neoplasm	0.000118	0.00136	CcSEcCtD
Crizotinib—Arrhythmia—Cisplatin—peripheral nervous system neoplasm	0.000118	0.00136	CcSEcCtD
Crizotinib—Neuropathy—Doxorubicin—peripheral nervous system neoplasm	0.000117	0.00135	CcSEcCtD
Crizotinib—Sepsis—Epirubicin—peripheral nervous system neoplasm	0.000117	0.00135	CcSEcCtD
Crizotinib—Leukopenia—Vincristine—peripheral nervous system neoplasm	0.000116	0.00134	CcSEcCtD
Crizotinib—Body temperature increased—Topotecan—peripheral nervous system neoplasm	0.000116	0.00133	CcSEcCtD
Crizotinib—Malnutrition—Cisplatin—peripheral nervous system neoplasm	0.000115	0.00133	CcSEcCtD
Crizotinib—Body temperature increased—Tretinoin—peripheral nervous system neoplasm	0.000115	0.00132	CcSEcCtD
Crizotinib—Body temperature increased—Isotretinoin—peripheral nervous system neoplasm	0.000115	0.00132	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Alitretinoin—peripheral nervous system neoplasm	0.000114	0.00132	CcSEcCtD
Crizotinib—Eye disorder—Etoposide—peripheral nervous system neoplasm	0.000113	0.0013	CcSEcCtD
Crizotinib—Blood alkaline phosphatase increased—Epirubicin—peripheral nervous system neoplasm	0.000113	0.0013	CcSEcCtD
Crizotinib—CSF1R—cerebellum—peripheral nervous system neoplasm	0.000112	0.00262	CbGeAlD
Crizotinib—Cardiac disorder—Etoposide—peripheral nervous system neoplasm	0.000112	0.00129	CcSEcCtD
Crizotinib—Hepatic function abnormal—Epirubicin—peripheral nervous system neoplasm	0.000112	0.00129	CcSEcCtD
Crizotinib—Oedema—Alitretinoin—peripheral nervous system neoplasm	0.00011	0.00127	CcSEcCtD
Crizotinib—Infection—Alitretinoin—peripheral nervous system neoplasm	0.000109	0.00126	CcSEcCtD
Crizotinib—Hepatic failure—Epirubicin—peripheral nervous system neoplasm	0.000109	0.00126	CcSEcCtD
Crizotinib—Mediastinal disorder—Etoposide—peripheral nervous system neoplasm	0.000109	0.00126	CcSEcCtD
Crizotinib—Sepsis—Doxorubicin—peripheral nervous system neoplasm	0.000109	0.00125	CcSEcCtD
Crizotinib—Vision blurred—Cisplatin—peripheral nervous system neoplasm	0.000108	0.00125	CcSEcCtD
Crizotinib—Shock—Alitretinoin—peripheral nervous system neoplasm	0.000108	0.00125	CcSEcCtD
Crizotinib—Nervous system disorder—Alitretinoin—peripheral nervous system neoplasm	0.000108	0.00125	CcSEcCtD
Crizotinib—Skin disorder—Alitretinoin—peripheral nervous system neoplasm	0.000107	0.00123	CcSEcCtD
Crizotinib—Anaemia—Cisplatin—peripheral nervous system neoplasm	0.000106	0.00123	CcSEcCtD
Crizotinib—Oedema—Vincristine—peripheral nervous system neoplasm	0.000106	0.00122	CcSEcCtD
Crizotinib—Infection—Vincristine—peripheral nervous system neoplasm	0.000105	0.00122	CcSEcCtD
Crizotinib—Asthenia—Topotecan—peripheral nervous system neoplasm	0.000105	0.00121	CcSEcCtD
Crizotinib—Blood alkaline phosphatase increased—Doxorubicin—peripheral nervous system neoplasm	0.000104	0.0012	CcSEcCtD
Crizotinib—Asthenia—Tretinoin—peripheral nervous system neoplasm	0.000104	0.0012	CcSEcCtD
Crizotinib—Asthenia—Isotretinoin—peripheral nervous system neoplasm	0.000104	0.0012	CcSEcCtD
Crizotinib—Nervous system disorder—Vincristine—peripheral nervous system neoplasm	0.000104	0.0012	CcSEcCtD
Crizotinib—Hepatic function abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000104	0.0012	CcSEcCtD
Crizotinib—Decreased appetite—Dactinomycin—peripheral nervous system neoplasm	0.000103	0.00119	CcSEcCtD
Crizotinib—Dysgeusia—Etoposide—peripheral nervous system neoplasm	0.000103	0.00119	CcSEcCtD
Crizotinib—Leukopenia—Cisplatin—peripheral nervous system neoplasm	0.000103	0.00119	CcSEcCtD
Crizotinib—Asthenia—Melphalan—peripheral nervous system neoplasm	0.000103	0.00119	CcSEcCtD
Crizotinib—Fatigue—Dactinomycin—peripheral nervous system neoplasm	0.000102	0.00118	CcSEcCtD
Crizotinib—Hepatic failure—Doxorubicin—peripheral nervous system neoplasm	0.000101	0.00116	CcSEcCtD
Crizotinib—Diarrhoea—Topotecan—peripheral nervous system neoplasm	0.0001	0.00116	CcSEcCtD
Crizotinib—Diarrhoea—Tretinoin—peripheral nervous system neoplasm	9.95e-05	0.00115	CcSEcCtD
Crizotinib—Diarrhoea—Isotretinoin—peripheral nervous system neoplasm	9.95e-05	0.00115	CcSEcCtD
Crizotinib—Paraesthesia—Alitretinoin—peripheral nervous system neoplasm	9.89e-05	0.00114	CcSEcCtD
Crizotinib—Dyspnoea—Alitretinoin—peripheral nervous system neoplasm	9.82e-05	0.00113	CcSEcCtD
Crizotinib—Diarrhoea—Melphalan—peripheral nervous system neoplasm	9.82e-05	0.00113	CcSEcCtD
Crizotinib—Diplopia—Epirubicin—peripheral nervous system neoplasm	9.81e-05	0.00113	CcSEcCtD
Crizotinib—Anaemia—Etoposide—peripheral nervous system neoplasm	9.74e-05	0.00112	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—peripheral nervous system neoplasm	9.73e-05	0.00112	CcSEcCtD
Crizotinib—Dyspepsia—Alitretinoin—peripheral nervous system neoplasm	9.7e-05	0.00112	CcSEcCtD
Crizotinib—Dizziness—Topotecan—peripheral nervous system neoplasm	9.69e-05	0.00112	CcSEcCtD
Crizotinib—Dizziness—Tretinoin—peripheral nervous system neoplasm	9.62e-05	0.00111	CcSEcCtD
Crizotinib—Dizziness—Isotretinoin—peripheral nervous system neoplasm	9.62e-05	0.00111	CcSEcCtD
Crizotinib—Decreased appetite—Alitretinoin—peripheral nervous system neoplasm	9.58e-05	0.0011	CcSEcCtD
Crizotinib—Paraesthesia—Vincristine—peripheral nervous system neoplasm	9.53e-05	0.0011	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	9.51e-05	0.0011	CcSEcCtD
Crizotinib—Fatigue—Alitretinoin—peripheral nervous system neoplasm	9.5e-05	0.00109	CcSEcCtD
Crizotinib—Face oedema—Epirubicin—peripheral nervous system neoplasm	9.47e-05	0.00109	CcSEcCtD
Crizotinib—Leukopenia—Etoposide—peripheral nervous system neoplasm	9.43e-05	0.00109	CcSEcCtD
Crizotinib—Constipation—Alitretinoin—peripheral nervous system neoplasm	9.42e-05	0.00109	CcSEcCtD
Crizotinib—Body temperature increased—Dactinomycin—peripheral nervous system neoplasm	9.39e-05	0.00108	CcSEcCtD
Crizotinib—Oedema—Cisplatin—peripheral nervous system neoplasm	9.39e-05	0.00108	CcSEcCtD
Crizotinib—Infection—Cisplatin—peripheral nervous system neoplasm	9.33e-05	0.00107	CcSEcCtD
Crizotinib—Vomiting—Topotecan—peripheral nervous system neoplasm	9.32e-05	0.00107	CcSEcCtD
Crizotinib—Loss of consciousness—Etoposide—peripheral nervous system neoplasm	9.26e-05	0.00107	CcSEcCtD
Crizotinib—Vomiting—Tretinoin—peripheral nervous system neoplasm	9.24e-05	0.00107	CcSEcCtD
Crizotinib—Vomiting—Isotretinoin—peripheral nervous system neoplasm	9.24e-05	0.00107	CcSEcCtD
Crizotinib—Rash—Topotecan—peripheral nervous system neoplasm	9.24e-05	0.00106	CcSEcCtD
Crizotinib—Dermatitis—Topotecan—peripheral nervous system neoplasm	9.23e-05	0.00106	CcSEcCtD
Crizotinib—Decreased appetite—Vincristine—peripheral nervous system neoplasm	9.23e-05	0.00106	CcSEcCtD
Crizotinib—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	9.21e-05	0.00106	CcSEcCtD
Crizotinib—Rash—Tretinoin—peripheral nervous system neoplasm	9.17e-05	0.00106	CcSEcCtD
Crizotinib—Rash—Isotretinoin—peripheral nervous system neoplasm	9.17e-05	0.00106	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	9.17e-05	0.00106	CcSEcCtD
Crizotinib—Dermatitis—Tretinoin—peripheral nervous system neoplasm	9.16e-05	0.00106	CcSEcCtD
Crizotinib—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	9.16e-05	0.00106	CcSEcCtD
Crizotinib—Fatigue—Vincristine—peripheral nervous system neoplasm	9.15e-05	0.00105	CcSEcCtD
Crizotinib—Vomiting—Melphalan—peripheral nervous system neoplasm	9.13e-05	0.00105	CcSEcCtD
Crizotinib—Skin disorder—Cisplatin—peripheral nervous system neoplasm	9.12e-05	0.00105	CcSEcCtD
Crizotinib—Constipation—Vincristine—peripheral nervous system neoplasm	9.08e-05	0.00105	CcSEcCtD
Crizotinib—Diplopia—Doxorubicin—peripheral nervous system neoplasm	9.08e-05	0.00105	CcSEcCtD
Crizotinib—Rash—Melphalan—peripheral nervous system neoplasm	9.05e-05	0.00104	CcSEcCtD
Crizotinib—Dermatitis—Melphalan—peripheral nervous system neoplasm	9.04e-05	0.00104	CcSEcCtD
Crizotinib—Hypokalaemia—Epirubicin—peripheral nervous system neoplasm	8.93e-05	0.00103	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	8.91e-05	0.00103	CcSEcCtD
Crizotinib—ABL1—cerebellum—peripheral nervous system neoplasm	8.89e-05	0.00207	CbGeAlD
Crizotinib—Aspartate aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	8.83e-05	0.00102	CcSEcCtD
Crizotinib—Face oedema—Doxorubicin—peripheral nervous system neoplasm	8.76e-05	0.00101	CcSEcCtD
Crizotinib—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	8.71e-05	0.001	CcSEcCtD
Crizotinib—Nausea—Topotecan—peripheral nervous system neoplasm	8.71e-05	0.001	CcSEcCtD
Crizotinib—Muscular weakness—Epirubicin—peripheral nervous system neoplasm	8.65e-05	0.000997	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	8.65e-05	0.000997	CcSEcCtD
Crizotinib—Nausea—Tretinoin—peripheral nervous system neoplasm	8.64e-05	0.000995	CcSEcCtD
Crizotinib—Nausea—Isotretinoin—peripheral nervous system neoplasm	8.64e-05	0.000995	CcSEcCtD
Crizotinib—Infection—Etoposide—peripheral nervous system neoplasm	8.55e-05	0.000985	CcSEcCtD
Crizotinib—Asthenia—Dactinomycin—peripheral nervous system neoplasm	8.53e-05	0.000982	CcSEcCtD
Crizotinib—Nausea—Melphalan—peripheral nervous system neoplasm	8.52e-05	0.000982	CcSEcCtD
Crizotinib—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	8.43e-05	0.000971	CcSEcCtD
Crizotinib—Body temperature increased—Vincristine—peripheral nervous system neoplasm	8.39e-05	0.000967	CcSEcCtD
Crizotinib—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	8.37e-05	0.000964	CcSEcCtD
Crizotinib—Skin disorder—Etoposide—peripheral nervous system neoplasm	8.35e-05	0.000963	CcSEcCtD
Crizotinib—Hypokalaemia—Doxorubicin—peripheral nervous system neoplasm	8.26e-05	0.000952	CcSEcCtD
Crizotinib—PLK4—Teniposide—Etoposide—peripheral nervous system neoplasm	8.23e-05	0.0269	CbGdCrCtD
Crizotinib—IGF1R—Idarubicin—Epirubicin—peripheral nervous system neoplasm	8.18e-05	0.0267	CbGdCrCtD
Crizotinib—Aspartate aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	8.17e-05	0.000942	CcSEcCtD
Crizotinib—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	8.16e-05	0.00094	CcSEcCtD
Crizotinib—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	8.13e-05	0.000937	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	8.11e-05	0.000934	CcSEcCtD
Crizotinib—Muscular weakness—Doxorubicin—peripheral nervous system neoplasm	8.01e-05	0.000922	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	8.01e-05	0.000922	CcSEcCtD
Crizotinib—Neutropenia—Epirubicin—peripheral nervous system neoplasm	7.93e-05	0.000913	CcSEcCtD
Crizotinib—Asthenia—Alitretinoin—peripheral nervous system neoplasm	7.91e-05	0.000911	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	7.88e-05	0.000908	CcSEcCtD
Crizotinib—Paraesthesia—Etoposide—peripheral nervous system neoplasm	7.72e-05	0.00089	CcSEcCtD
Crizotinib—Weight decreased—Epirubicin—peripheral nervous system neoplasm	7.67e-05	0.000884	CcSEcCtD
Crizotinib—Dyspnoea—Etoposide—peripheral nervous system neoplasm	7.67e-05	0.000884	CcSEcCtD
Crizotinib—Asthenia—Vincristine—peripheral nervous system neoplasm	7.62e-05	0.000878	CcSEcCtD
Crizotinib—Pneumonia—Epirubicin—peripheral nervous system neoplasm	7.6e-05	0.000876	CcSEcCtD
Crizotinib—IGF1R—Idarubicin—Doxorubicin—peripheral nervous system neoplasm	7.56e-05	0.0247	CbGdCrCtD
Crizotinib—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	7.56e-05	0.000871	CcSEcCtD
Crizotinib—Infestation—Epirubicin—peripheral nervous system neoplasm	7.56e-05	0.000871	CcSEcCtD
Crizotinib—Vomiting—Dactinomycin—peripheral nervous system neoplasm	7.56e-05	0.000871	CcSEcCtD
Crizotinib—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	7.54e-05	0.000869	CcSEcCtD
Crizotinib—Rash—Dactinomycin—peripheral nervous system neoplasm	7.49e-05	0.000863	CcSEcCtD
Crizotinib—Decreased appetite—Etoposide—peripheral nervous system neoplasm	7.48e-05	0.000861	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	7.43e-05	0.000856	CcSEcCtD
Crizotinib—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	7.42e-05	0.000855	CcSEcCtD
Crizotinib—Fatigue—Etoposide—peripheral nervous system neoplasm	7.42e-05	0.000854	CcSEcCtD
Crizotinib—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	7.41e-05	0.000854	CcSEcCtD
Crizotinib—Constipation—Etoposide—peripheral nervous system neoplasm	7.36e-05	0.000847	CcSEcCtD
Crizotinib—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	7.34e-05	0.000845	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	7.29e-05	0.00084	CcSEcCtD
Crizotinib—Dizziness—Alitretinoin—peripheral nervous system neoplasm	7.29e-05	0.00084	CcSEcCtD
Crizotinib—Diarrhoea—Vincristine—peripheral nervous system neoplasm	7.27e-05	0.000837	CcSEcCtD
Crizotinib—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	7.15e-05	0.000824	CcSEcCtD
Crizotinib—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	7.1e-05	0.000818	CcSEcCtD
Crizotinib—Nausea—Dactinomycin—peripheral nervous system neoplasm	7.06e-05	0.000813	CcSEcCtD
Crizotinib—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	7.04e-05	0.000811	CcSEcCtD
Crizotinib—Dizziness—Vincristine—peripheral nervous system neoplasm	7.02e-05	0.000809	CcSEcCtD
Crizotinib—Vomiting—Alitretinoin—peripheral nervous system neoplasm	7.01e-05	0.000807	CcSEcCtD
Crizotinib—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	6.99e-05	0.000806	CcSEcCtD
Crizotinib—Infestation—Doxorubicin—peripheral nervous system neoplasm	6.99e-05	0.000806	CcSEcCtD
Crizotinib—Rash—Alitretinoin—peripheral nervous system neoplasm	6.95e-05	0.0008	CcSEcCtD
Crizotinib—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	6.94e-05	0.0008	CcSEcCtD
Crizotinib—Bradycardia—Epirubicin—peripheral nervous system neoplasm	6.91e-05	0.000796	CcSEcCtD
Crizotinib—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	6.86e-05	0.00079	CcSEcCtD
Crizotinib—Body temperature increased—Etoposide—peripheral nervous system neoplasm	6.8e-05	0.000783	CcSEcCtD
Crizotinib—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	6.75e-05	0.000778	CcSEcCtD
Crizotinib—Vomiting—Vincristine—peripheral nervous system neoplasm	6.75e-05	0.000778	CcSEcCtD
Crizotinib—Asthenia—Cisplatin—peripheral nervous system neoplasm	6.74e-05	0.000776	CcSEcCtD
Crizotinib—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	6.7e-05	0.000772	CcSEcCtD
Crizotinib—Rash—Vincristine—peripheral nervous system neoplasm	6.7e-05	0.000771	CcSEcCtD
Crizotinib—Dermatitis—Vincristine—peripheral nervous system neoplasm	6.69e-05	0.000771	CcSEcCtD
Crizotinib—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	6.69e-05	0.00077	CcSEcCtD
Crizotinib—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	6.65e-05	0.000766	CcSEcCtD
Crizotinib—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	6.62e-05	0.000762	CcSEcCtD
Crizotinib—CDK7—Idarubicin—Epirubicin—peripheral nervous system neoplasm	6.59e-05	0.0215	CbGdCrCtD
Crizotinib—CDK7—Daunorubicin—Epirubicin—peripheral nervous system neoplasm	6.59e-05	0.0215	CbGdCrCtD
Crizotinib—CDK7—Doxorubicin—Epirubicin—peripheral nervous system neoplasm	6.59e-05	0.0215	CbGdCrCtD
Crizotinib—Nausea—Alitretinoin—peripheral nervous system neoplasm	6.55e-05	0.000754	CcSEcCtD
Crizotinib—Visual impairment—Epirubicin—peripheral nervous system neoplasm	6.54e-05	0.000754	CcSEcCtD
Crizotinib—AURKA—Teniposide—Etoposide—peripheral nervous system neoplasm	6.45e-05	0.0211	CbGdCrCtD
Crizotinib—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	6.42e-05	0.00074	CcSEcCtD
Crizotinib—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	6.39e-05	0.000737	CcSEcCtD
Crizotinib—Eye disorder—Epirubicin—peripheral nervous system neoplasm	6.34e-05	0.000731	CcSEcCtD
Crizotinib—ABCB1—trigeminal ganglion—peripheral nervous system neoplasm	6.34e-05	0.00148	CbGeAlD
Crizotinib—Nausea—Vincristine—peripheral nervous system neoplasm	6.31e-05	0.000727	CcSEcCtD
Crizotinib—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	6.3e-05	0.000726	CcSEcCtD
Crizotinib—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	6.25e-05	0.00072	CcSEcCtD
Crizotinib—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	6.2e-05	0.000714	CcSEcCtD
Crizotinib—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	6.19e-05	0.000713	CcSEcCtD
Crizotinib—Asthenia—Etoposide—peripheral nervous system neoplasm	6.17e-05	0.000711	CcSEcCtD
Crizotinib—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	6.16e-05	0.000709	CcSEcCtD
Crizotinib—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	6.12e-05	0.000705	CcSEcCtD
Crizotinib—CDK7—Daunorubicin—Doxorubicin—peripheral nervous system neoplasm	6.1e-05	0.0199	CbGdCrCtD
Crizotinib—CDK7—Idarubicin—Doxorubicin—peripheral nervous system neoplasm	6.1e-05	0.0199	CbGdCrCtD
Crizotinib—CDK7—Epirubicin—Doxorubicin—peripheral nervous system neoplasm	6.1e-05	0.0199	CbGdCrCtD
Crizotinib—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	6.06e-05	0.000699	CcSEcCtD
Crizotinib—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	6.05e-05	0.000697	CcSEcCtD
Crizotinib—Vomiting—Cisplatin—peripheral nervous system neoplasm	5.97e-05	0.000688	CcSEcCtD
Crizotinib—Rash—Cisplatin—peripheral nervous system neoplasm	5.92e-05	0.000682	CcSEcCtD
Crizotinib—Dermatitis—Cisplatin—peripheral nervous system neoplasm	5.91e-05	0.000681	CcSEcCtD
Crizotinib—Malnutrition—Epirubicin—peripheral nervous system neoplasm	5.91e-05	0.000681	CcSEcCtD
Crizotinib—Diarrhoea—Etoposide—peripheral nervous system neoplasm	5.89e-05	0.000678	CcSEcCtD
Crizotinib—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	5.87e-05	0.000676	CcSEcCtD
Crizotinib—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	5.83e-05	0.000671	CcSEcCtD
Crizotinib—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	5.79e-05	0.000667	CcSEcCtD
Crizotinib—Dizziness—Etoposide—peripheral nervous system neoplasm	5.69e-05	0.000655	CcSEcCtD
Crizotinib—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	5.66e-05	0.000652	CcSEcCtD
Crizotinib—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	5.61e-05	0.000646	CcSEcCtD
Crizotinib—Nausea—Cisplatin—peripheral nervous system neoplasm	5.58e-05	0.000643	CcSEcCtD
Crizotinib—Vision blurred—Epirubicin—peripheral nervous system neoplasm	5.57e-05	0.000641	CcSEcCtD
Crizotinib—Vomiting—Etoposide—peripheral nervous system neoplasm	5.47e-05	0.00063	CcSEcCtD
Crizotinib—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	5.47e-05	0.00063	CcSEcCtD
Crizotinib—Anaemia—Epirubicin—peripheral nervous system neoplasm	5.46e-05	0.000629	CcSEcCtD
Crizotinib—Rash—Etoposide—peripheral nervous system neoplasm	5.42e-05	0.000625	CcSEcCtD
Crizotinib—Dermatitis—Etoposide—peripheral nervous system neoplasm	5.42e-05	0.000624	CcSEcCtD
Crizotinib—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	5.35e-05	0.000617	CcSEcCtD
Crizotinib—Syncope—Epirubicin—peripheral nervous system neoplasm	5.3e-05	0.00061	CcSEcCtD
Crizotinib—Leukopenia—Epirubicin—peripheral nervous system neoplasm	5.29e-05	0.000609	CcSEcCtD
Crizotinib—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	5.19e-05	0.000598	CcSEcCtD
Crizotinib—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	5.15e-05	0.000594	CcSEcCtD
Crizotinib—Nausea—Etoposide—peripheral nervous system neoplasm	5.11e-05	0.000589	CcSEcCtD
Crizotinib—Anaemia—Doxorubicin—peripheral nervous system neoplasm	5.05e-05	0.000582	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	5e-05	0.000575	CcSEcCtD
Crizotinib—Syncope—Doxorubicin—peripheral nervous system neoplasm	4.9e-05	0.000565	CcSEcCtD
Crizotinib—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	4.89e-05	0.000564	CcSEcCtD
Crizotinib—Oedema—Epirubicin—peripheral nervous system neoplasm	4.82e-05	0.000556	CcSEcCtD
Crizotinib—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	4.8e-05	0.000554	CcSEcCtD
Crizotinib—Infection—Epirubicin—peripheral nervous system neoplasm	4.79e-05	0.000552	CcSEcCtD
Crizotinib—Shock—Epirubicin—peripheral nervous system neoplasm	4.74e-05	0.000547	CcSEcCtD
Crizotinib—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	4.73e-05	0.000545	CcSEcCtD
Crizotinib—Skin disorder—Epirubicin—peripheral nervous system neoplasm	4.68e-05	0.00054	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	4.62e-05	0.000532	CcSEcCtD
Crizotinib—Oedema—Doxorubicin—peripheral nervous system neoplasm	4.46e-05	0.000514	CcSEcCtD
Crizotinib—Infection—Doxorubicin—peripheral nervous system neoplasm	4.43e-05	0.000511	CcSEcCtD
Crizotinib—Shock—Doxorubicin—peripheral nervous system neoplasm	4.39e-05	0.000506	CcSEcCtD
Crizotinib—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	4.38e-05	0.000504	CcSEcCtD
Crizotinib—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	4.33e-05	0.000499	CcSEcCtD
Crizotinib—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	4.33e-05	0.000499	CcSEcCtD
Crizotinib—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	4.3e-05	0.000495	CcSEcCtD
Crizotinib—PLK4—Doxorubicin—Epirubicin—peripheral nervous system neoplasm	4.29e-05	0.014	CbGdCrCtD
Crizotinib—PLK4—Idarubicin—Epirubicin—peripheral nervous system neoplasm	4.29e-05	0.014	CbGdCrCtD
Crizotinib—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	4.24e-05	0.000489	CcSEcCtD
Crizotinib—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	4.19e-05	0.000483	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	4.16e-05	0.00048	CcSEcCtD
Crizotinib—Fatigue—Epirubicin—peripheral nervous system neoplasm	4.16e-05	0.000479	CcSEcCtD
Crizotinib—Constipation—Epirubicin—peripheral nervous system neoplasm	4.12e-05	0.000475	CcSEcCtD
Crizotinib—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	4.01e-05	0.000462	CcSEcCtD
Crizotinib—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	3.98e-05	0.000458	CcSEcCtD
Crizotinib—PLK4—Idarubicin—Doxorubicin—peripheral nervous system neoplasm	3.97e-05	0.013	CbGdCrCtD
Crizotinib—PLK4—Epirubicin—Doxorubicin—peripheral nervous system neoplasm	3.97e-05	0.013	CbGdCrCtD
Crizotinib—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	3.93e-05	0.000452	CcSEcCtD
Crizotinib—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	3.88e-05	0.000447	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	3.85e-05	0.000444	CcSEcCtD
Crizotinib—Fatigue—Doxorubicin—peripheral nervous system neoplasm	3.85e-05	0.000443	CcSEcCtD
Crizotinib—Constipation—Doxorubicin—peripheral nervous system neoplasm	3.82e-05	0.00044	CcSEcCtD
Crizotinib—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	3.81e-05	0.000439	CcSEcCtD
Crizotinib—ABL1—Daunorubicin—Epirubicin—peripheral nervous system neoplasm	3.61e-05	0.0118	CbGdCrCtD
Crizotinib—ABL1—Idarubicin—Epirubicin—peripheral nervous system neoplasm	3.61e-05	0.0118	CbGdCrCtD
Crizotinib—ABL1—Doxorubicin—Epirubicin—peripheral nervous system neoplasm	3.61e-05	0.0118	CbGdCrCtD
Crizotinib—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	3.53e-05	0.000406	CcSEcCtD
Crizotinib—Asthenia—Epirubicin—peripheral nervous system neoplasm	3.46e-05	0.000399	CcSEcCtD
Crizotinib—AURKA—Doxorubicin—Epirubicin—peripheral nervous system neoplasm	3.36e-05	0.011	CbGdCrCtD
Crizotinib—AURKA—Daunorubicin—Epirubicin—peripheral nervous system neoplasm	3.36e-05	0.011	CbGdCrCtD
Crizotinib—AURKA—Idarubicin—Epirubicin—peripheral nervous system neoplasm	3.36e-05	0.011	CbGdCrCtD
Crizotinib—ABL1—Epirubicin—Doxorubicin—peripheral nervous system neoplasm	3.34e-05	0.0109	CbGdCrCtD
Crizotinib—ABL1—Daunorubicin—Doxorubicin—peripheral nervous system neoplasm	3.34e-05	0.0109	CbGdCrCtD
Crizotinib—ABL1—Idarubicin—Doxorubicin—peripheral nervous system neoplasm	3.34e-05	0.0109	CbGdCrCtD
Crizotinib—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	3.3e-05	0.00038	CcSEcCtD
Crizotinib—Asthenia—Doxorubicin—peripheral nervous system neoplasm	3.2e-05	0.000369	CcSEcCtD
Crizotinib—Dizziness—Epirubicin—peripheral nervous system neoplasm	3.19e-05	0.000367	CcSEcCtD
Crizotinib—AURKA—Epirubicin—Doxorubicin—peripheral nervous system neoplasm	3.11e-05	0.0102	CbGdCrCtD
Crizotinib—AURKA—Daunorubicin—Doxorubicin—peripheral nervous system neoplasm	3.11e-05	0.0102	CbGdCrCtD
Crizotinib—AURKA—Idarubicin—Doxorubicin—peripheral nervous system neoplasm	3.11e-05	0.0102	CbGdCrCtD
Crizotinib—Vomiting—Epirubicin—peripheral nervous system neoplasm	3.07e-05	0.000353	CcSEcCtD
Crizotinib—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	3.05e-05	0.000352	CcSEcCtD
Crizotinib—Rash—Epirubicin—peripheral nervous system neoplasm	3.04e-05	0.00035	CcSEcCtD
Crizotinib—Dermatitis—Epirubicin—peripheral nervous system neoplasm	3.04e-05	0.00035	CcSEcCtD
Crizotinib—Dizziness—Doxorubicin—peripheral nervous system neoplasm	2.95e-05	0.00034	CcSEcCtD
Crizotinib—Nausea—Epirubicin—peripheral nervous system neoplasm	2.86e-05	0.00033	CcSEcCtD
Crizotinib—Vomiting—Doxorubicin—peripheral nervous system neoplasm	2.84e-05	0.000327	CcSEcCtD
Crizotinib—Rash—Doxorubicin—peripheral nervous system neoplasm	2.81e-05	0.000324	CcSEcCtD
Crizotinib—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	2.81e-05	0.000324	CcSEcCtD
Crizotinib—ABCB1—cerebellum—peripheral nervous system neoplasm	2.76e-05	0.000644	CbGeAlD
Crizotinib—Nausea—Doxorubicin—peripheral nervous system neoplasm	2.65e-05	0.000305	CcSEcCtD
Crizotinib—IRAK1—Innate Immune System—AKT1—peripheral nervous system neoplasm	2.3e-06	2.06e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—NRAS—peripheral nervous system neoplasm	2.3e-06	2.06e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—NRAS—peripheral nervous system neoplasm	2.3e-06	2.06e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.3e-06	2.06e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—HRAS—peripheral nervous system neoplasm	2.28e-06	2.04e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.27e-06	2.03e-05	CbGpPWpGaD
Crizotinib—TBK1—Immune System—AKT1—peripheral nervous system neoplasm	2.27e-06	2.03e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—HRAS—peripheral nervous system neoplasm	2.27e-06	2.03e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—NRAS—peripheral nervous system neoplasm	2.26e-06	2.02e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	2.26e-06	2.02e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.24e-06	2.01e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—BCHE—peripheral nervous system neoplasm	2.24e-06	2e-05	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—AKT1—peripheral nervous system neoplasm	2.24e-06	2e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.23e-06	2e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	2.23e-06	2e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—TP53—peripheral nervous system neoplasm	2.23e-06	1.99e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—PTPN11—peripheral nervous system neoplasm	2.22e-06	1.99e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—NRAS—peripheral nervous system neoplasm	2.22e-06	1.99e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.21e-06	1.97e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	2.21e-06	1.97e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.2e-06	1.97e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—NRAS—peripheral nervous system neoplasm	2.19e-06	1.96e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.18e-06	1.95e-05	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—AKT1—peripheral nervous system neoplasm	2.17e-06	1.95e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—HRAS—peripheral nervous system neoplasm	2.17e-06	1.94e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.17e-06	1.94e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.17e-06	1.94e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.15e-06	1.93e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—ERBB2—peripheral nervous system neoplasm	2.15e-06	1.92e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.14e-06	1.91e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—ERBB2—peripheral nervous system neoplasm	2.14e-06	1.91e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—HRAS—peripheral nervous system neoplasm	2.13e-06	1.91e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.12e-06	1.9e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—TH—peripheral nervous system neoplasm	2.1e-06	1.88e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—KNG1—peripheral nervous system neoplasm	2.1e-06	1.88e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.08e-06	1.86e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—NRAS—peripheral nervous system neoplasm	2.08e-06	1.86e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—GNAS—peripheral nervous system neoplasm	2.07e-06	1.85e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—HRAS—peripheral nervous system neoplasm	2.07e-06	1.85e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.06e-06	1.84e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—PTPN11—peripheral nervous system neoplasm	2.05e-06	1.84e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.05e-06	1.84e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—HRAS—peripheral nervous system neoplasm	2.05e-06	1.84e-05	CbGpPWpGaD
Crizotinib—JAK3—Immune System—AKT1—peripheral nervous system neoplasm	2.05e-06	1.84e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—AKT1—peripheral nervous system neoplasm	2.05e-06	1.84e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—HRAS—peripheral nervous system neoplasm	2.04e-06	1.83e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—AKT1—peripheral nervous system neoplasm	2.04e-06	1.83e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—HRAS—peripheral nervous system neoplasm	2.04e-06	1.83e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—NRAS—peripheral nervous system neoplasm	2.03e-06	1.82e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	2.03e-06	1.82e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.03e-06	1.82e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.03e-06	1.81e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—NRAS—peripheral nervous system neoplasm	2.02e-06	1.8e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—AKT1—peripheral nervous system neoplasm	2.01e-06	1.8e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—ERBB2—peripheral nervous system neoplasm	2.01e-06	1.8e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—HRAS—peripheral nervous system neoplasm	2e-06	1.79e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—AKT1—peripheral nervous system neoplasm	2e-06	1.79e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ENO2—peripheral nervous system neoplasm	2e-06	1.79e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	2e-06	1.79e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2e-06	1.79e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—HRAS—peripheral nervous system neoplasm	1.99e-06	1.78e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—HRAS—peripheral nervous system neoplasm	1.98e-06	1.78e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—PTPN11—peripheral nervous system neoplasm	1.97e-06	1.76e-05	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	1.97e-06	1.76e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	1.95e-06	1.75e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—TP53—peripheral nervous system neoplasm	1.95e-06	1.75e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	1.95e-06	1.75e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—HRAS—peripheral nervous system neoplasm	1.92e-06	1.72e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—AKT1—peripheral nervous system neoplasm	1.92e-06	1.72e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.91e-06	1.71e-05	CbGpPWpGaD
Crizotinib—CDK7—Gene Expression—AKT1—peripheral nervous system neoplasm	1.9e-06	1.71e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.89e-06	1.69e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	1.88e-06	1.68e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—AKT1—peripheral nervous system neoplasm	1.88e-06	1.68e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	1.88e-06	1.68e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—HRAS—peripheral nervous system neoplasm	1.87e-06	1.67e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—NRAS—peripheral nervous system neoplasm	1.86e-06	1.67e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.86e-06	1.67e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—ERBB2—peripheral nervous system neoplasm	1.85e-06	1.66e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.83e-06	1.64e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.83e-06	1.64e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.83e-06	1.64e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—AKT1—peripheral nervous system neoplasm	1.83e-06	1.64e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—PTPN11—peripheral nervous system neoplasm	1.82e-06	1.63e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—AKT1—peripheral nervous system neoplasm	1.81e-06	1.62e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.8e-06	1.61e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—AKT1—peripheral nervous system neoplasm	1.8e-06	1.61e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—AKT1—peripheral nervous system neoplasm	1.8e-06	1.61e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.79e-06	1.61e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—AKT1—peripheral nervous system neoplasm	1.77e-06	1.58e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.76e-06	1.58e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—ERBB2—peripheral nervous system neoplasm	1.76e-06	1.57e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—AKT1—peripheral nervous system neoplasm	1.76e-06	1.57e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.75e-06	1.57e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—AKT1—peripheral nervous system neoplasm	1.75e-06	1.57e-05	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	1.74e-06	1.56e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—MYC—peripheral nervous system neoplasm	1.73e-06	1.55e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—TP53—peripheral nervous system neoplasm	1.73e-06	1.55e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.72e-06	1.54e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—GNAS—peripheral nervous system neoplasm	1.72e-06	1.54e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.71e-06	1.53e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.71e-06	1.53e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.7e-06	1.53e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—AKT1—peripheral nervous system neoplasm	1.69e-06	1.52e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—BCHE—peripheral nervous system neoplasm	1.69e-06	1.51e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.69e-06	1.51e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—ABCB1—peripheral nervous system neoplasm	1.69e-06	1.51e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—HRAS—peripheral nervous system neoplasm	1.68e-06	1.51e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—HRAS—peripheral nervous system neoplasm	1.68e-06	1.5e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.68e-06	1.5e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.67e-06	1.5e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.67e-06	1.5e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—HRAS—peripheral nervous system neoplasm	1.65e-06	1.48e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—AKT1—peripheral nervous system neoplasm	1.65e-06	1.48e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.64e-06	1.47e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—NRAS—peripheral nervous system neoplasm	1.63e-06	1.46e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—NRAS—peripheral nervous system neoplasm	1.62e-06	1.45e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—HRAS—peripheral nervous system neoplasm	1.62e-06	1.45e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—ERBB2—peripheral nervous system neoplasm	1.62e-06	1.45e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.61e-06	1.44e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	1.61e-06	1.44e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.61e-06	1.44e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.61e-06	1.44e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.6e-06	1.43e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—HRAS—peripheral nervous system neoplasm	1.6e-06	1.43e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—TH—peripheral nervous system neoplasm	1.59e-06	1.42e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.57e-06	1.41e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.56e-06	1.39e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—ERBB2—peripheral nervous system neoplasm	1.56e-06	1.39e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.55e-06	1.39e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—NRAS—peripheral nervous system neoplasm	1.53e-06	1.37e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—HRAS—peripheral nervous system neoplasm	1.52e-06	1.36e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.5e-06	1.34e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—HRAS—peripheral nervous system neoplasm	1.49e-06	1.33e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—AKT1—peripheral nervous system neoplasm	1.49e-06	1.33e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—AKT1—peripheral nervous system neoplasm	1.48e-06	1.33e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—HRAS—peripheral nervous system neoplasm	1.47e-06	1.32e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—AKT1—peripheral nervous system neoplasm	1.46e-06	1.31e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.44e-06	1.29e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—ERBB2—peripheral nervous system neoplasm	1.44e-06	1.29e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.43e-06	1.28e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—AKT1—peripheral nervous system neoplasm	1.43e-06	1.28e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	1.43e-06	1.28e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.42e-06	1.28e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	1.42e-06	1.28e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.42e-06	1.27e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—AKT1—peripheral nervous system neoplasm	1.41e-06	1.27e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—NRAS—peripheral nervous system neoplasm	1.41e-06	1.26e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.4e-06	1.25e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.39e-06	1.24e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.38e-06	1.23e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—HRAS—peripheral nervous system neoplasm	1.36e-06	1.22e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.34e-06	1.2e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—AKT1—peripheral nervous system neoplasm	1.34e-06	1.2e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.34e-06	1.2e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—NRAS—peripheral nervous system neoplasm	1.34e-06	1.2e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.34e-06	1.2e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.33e-06	1.19e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.32e-06	1.18e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.32e-06	1.18e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.32e-06	1.18e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—MYC—peripheral nervous system neoplasm	1.31e-06	1.18e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—AKT1—peripheral nervous system neoplasm	1.31e-06	1.18e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.3e-06	1.17e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—AKT1—peripheral nervous system neoplasm	1.3e-06	1.17e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.3e-06	1.16e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GNAS—peripheral nervous system neoplasm	1.3e-06	1.16e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.28e-06	1.15e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.27e-06	1.14e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.26e-06	1.13e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	1.26e-06	1.13e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.26e-06	1.13e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.25e-06	1.12e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—NRAS—peripheral nervous system neoplasm	1.24e-06	1.11e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	1.23e-06	1.1e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.22e-06	1.1e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.22e-06	1.09e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.21e-06	1.09e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—AKT1—peripheral nervous system neoplasm	1.2e-06	1.08e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—HRAS—peripheral nervous system neoplasm	1.19e-06	1.07e-05	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.19e-06	1.06e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—HRAS—peripheral nervous system neoplasm	1.19e-06	1.06e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—NRAS—peripheral nervous system neoplasm	1.18e-06	1.06e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.18e-06	1.06e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.18e-06	1.05e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.16e-06	1.04e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—MYC—peripheral nervous system neoplasm	1.15e-06	1.03e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.14e-06	1.02e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—HRAS—peripheral nervous system neoplasm	1.12e-06	1e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.11e-06	9.98e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.1e-06	9.83e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—NRAS—peripheral nervous system neoplasm	1.09e-06	9.79e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.08e-06	9.69e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.08e-06	9.67e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.08e-06	9.67e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.06e-06	9.45e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—AKT1—peripheral nervous system neoplasm	1.05e-06	9.44e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.05e-06	9.4e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—AKT1—peripheral nervous system neoplasm	1.05e-06	9.4e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	1.04e-06	9.32e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.04e-06	9.27e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.03e-06	9.24e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—HRAS—peripheral nervous system neoplasm	1.03e-06	9.24e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.03e-06	9.19e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—MYC—peripheral nervous system neoplasm	1.02e-06	9.12e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.01e-06	9.01e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—peripheral nervous system neoplasm	9.97e-07	8.92e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	9.93e-07	8.89e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	9.87e-07	8.84e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—AKT1—peripheral nervous system neoplasm	9.87e-07	8.83e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MYC—peripheral nervous system neoplasm	9.83e-07	8.8e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	9.82e-07	8.79e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—HRAS—peripheral nervous system neoplasm	9.79e-07	8.76e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	9.78e-07	8.76e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	9.53e-07	8.53e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	9.27e-07	8.3e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MYC—peripheral nervous system neoplasm	9.2e-07	8.24e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	9.14e-07	8.18e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CASP3—peripheral nervous system neoplasm	9.13e-07	8.18e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—AKT1—peripheral nervous system neoplasm	9.11e-07	8.16e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—HRAS—peripheral nervous system neoplasm	9.04e-07	8.09e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	8.67e-07	7.76e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—HRAS—peripheral nervous system neoplasm	8.66e-07	7.76e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NRAS—peripheral nervous system neoplasm	8.65e-07	7.74e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—AKT1—peripheral nervous system neoplasm	8.64e-07	7.74e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	8.42e-07	7.54e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—peripheral nervous system neoplasm	8.07e-07	7.23e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MYC—peripheral nervous system neoplasm	8.06e-07	7.21e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—HRAS—peripheral nervous system neoplasm	8e-07	7.16e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	7.99e-07	7.15e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—AKT1—peripheral nervous system neoplasm	7.98e-07	7.14e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	7.84e-07	7.02e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—HRAS—peripheral nervous system neoplasm	7.72e-07	6.91e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NRAS—peripheral nervous system neoplasm	7.66e-07	6.86e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—AKT1—peripheral nervous system neoplasm	7.65e-07	6.85e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—peripheral nervous system neoplasm	7.55e-07	6.76e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	7.22e-07	6.47e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MYC—peripheral nervous system neoplasm	7.13e-07	6.39e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—AKT1—peripheral nervous system neoplasm	7.06e-07	6.32e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—AKT1—peripheral nervous system neoplasm	6.82e-07	6.1e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—peripheral nervous system neoplasm	6.62e-07	5.92e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	6.38e-07	5.71e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HRAS—peripheral nervous system neoplasm	6.33e-07	5.67e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—peripheral nervous system neoplasm	5.86e-07	5.24e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HRAS—peripheral nervous system neoplasm	5.6e-07	5.02e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—AKT1—peripheral nervous system neoplasm	5.59e-07	5e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—AKT1—peripheral nervous system neoplasm	4.95e-07	4.43e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—AKT1—peripheral nervous system neoplasm	4.64e-07	4.15e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—AKT1—peripheral nervous system neoplasm	3.5e-07	3.13e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	2.16e-07	1.93e-06	CbGpPWpGaD
